@ConfortZone Actually, they only started selling the medical thing this july, this means it will only be reflected in the 3rd quarter, not this 2nd quarter.
Additional Listing Announcement /Subdivision of Shares SUPERCOMNET TECHNOLOGIES BERHAD
1. Details of Corporate Proposal Involve issuance of new type/class of securities ? No Types of corporate proposal Exercise of Warrants Details of corporate proposal Exercise of the 200,000 Warrants 2019/2024 to subscribe for 200,000 new Ordinary Shares No. of shares issued under this corporate proposal 200,000 Issue price per share ($$) Malaysian Ringgit (MYR) 0.6500 Par Value($$) (if applicable) Latest issued share capital after the above corporate proposal in the following Units 643,200,000 Issued Share Capital ($$) Malaysian Ringgit (MYR) 107,140,000.000 Listing Date 11 Aug 2020
Initiation Supercomnet Technologies Bhd (SCT MK/BUY/RM1.52/Target: RM1.98) A Shooting Comet
• Initiate coverage with BUY call and target price of RM1.98 based on 30x 2021F PE. Scomnet is the direct beneficiary riding on the explosive demand for critical medical devices, being the sole supplier of FDA-certified components to western medical-tech giants such as Edward Lifesciences, Ambu Medical and Mermaid Medical Group.
• Stellar earnings track record. Since the acquisition of the remaining 80% stake of its medical subsidiary SMP in early-18, Scomnet recorded the ninth consecutive quarter of yoy earnings growth, and is poised to ride on the impending acceleration of healthcare equipment demand in the US and Europe. To note, Scomnet recorded an impressive 5-year net profit CAGR growth of 45% in 2015-19.
• Three-pronged strategy to fuel growth. Scomnet is poised for a new leg of growth which will anchor a 3-year revenue/net profit CAGR of 18/30%. This will be supported by: a) key customer’s aggressive growth, b) increase in the orderbook in tandem with the growth of global healthcare consumption, and c) efficiency improvement and capacity expansion.
• Capacity expansion to accelerate earnings. Scomnet’s utilisation rate for its medical segment has increased close to 90%(from 70%) to capture the overwhelming COVID-19 orderbooks, and has allocated RM7m-10m capex for capacity expansion, with second floor capacity to be lifted by 10-12.5% in the coming two months, followed by the new building which could potentially elevate capacity by 80% upon completion in 1-1.5 years.
• Forecasting a 3-year net profit CAGR of 30%. We estimate Scomnet to register core net profit of RM29.5m/RM42.5m in 2020/21 which implies earnings growth of 52%/44% respectively. This is on the back of a 3-year revenue CAGR of 18% whereby growth will be mainly driven by higher orders and contribution from SMP’s medical cables fulfilling huge COVID-19-induced demand.
Explaining the matter, he said, the D614G mutation was discovered by scientists in July and it is likely to mean the study on existing vaccines to be incomplete or ineffective against the mutation.
angmodan .. yes. but they go develop to industry linked this company. so when big company joint venture with small firm. price of small firm will goes up like rocket. see today nihsin rocket already
- a cash rich company with zero borrowings - strong and reliable management - forward moving core business that constantly develops solutions for market requirements - constant upward moving revenue + profit margin - strong ties with international markets
really looking forward to their next qtr report. RM2 will be history very soon imo.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
vin777
2 posts
Posted by vin777 > 2020-08-11 17:54 | Report Abuse
hoot ah